R2810-ONC-1788/TROG 17.11 - CPOST - TROG Cancer Research

By w.paterson
21 June, 2021
0 Comments

A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma

Primary Sponsor

Collaborating Groups

TROG Cancer Research

Accrual Target

412

Final Accrual

415

Closing Date of Accrual

20 August 2024

Trial Chairperson

Prof Sandro Porceddu - Princess Alexandra Hospital

Trial Contact

qa@trog.com.au

David, Jasmine and Susan Goode, re Kokoda Challenge to support TROG Cancer Research

27 May, 2025

Intrepid trekkers to take on Kokoda Challenge for TROG

Clinical Trials Day celebrations help spread the work about TROG’s work

LATEST NEWS: 27 MAY 2025 TROG members and staff

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma

TROG 18.06 – FIG

TROG 20.03 – AVATAR

Related Post

Intrepid trekkers to take on Kokoda Challenge for TROG

Clinical Trials Day celebrations help spread the work about TROG’s work